February 24, 2015

Mylan has been appointed as the exclusive India distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, by Gilead Sciences. 

February 9, 2015

Mylan Inc. and its subsidiary Mylan Pharmaceuticals are being sued by Bayer Healthcare, Bayer Healthcare Pharmaceuticals and Onyx Pharamceuticals in relation to the filing of an abbreviated new drug application for sorafenib tablets, the generic version of Nexavar. 

 

February 2, 2015

Mylan announced that it will acquire certain businesses from specialty women's healthcare company Famy Care Limited for $750 million, with additional contingent payments of up to $50 million. 

January 15, 2015

Mylan on Thursday announced the launch of lamivudine tablets, 100 mg, the generic version of Epivir-HBV from GlaxoSmithKline. 

January 5, 2015

Mylan announced the introduction of valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. 

December 22, 2014

Mylan has announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day (twice weekly), which is the generic version of Novartis' Vivelle-DOT.

December 11, 2014

Mylan on Thursday announced the launch of methocarbamol injection USP, 100 mg. 

December 11, 2014

Mylan on Thursday announced the launch of prednisolone sodium phosphate orally disintegrating tablets in 10-mg, 15-mg and 30-mg dosage strengths. 

 

December 10, 2014

Mylan on Wednesday launched its celecoxib capsules in 50-, 100-, 200- and 400-mg dosage strengths. The drug is one of the first available generic versions of Celebrex capsules from Pfizer.

December 4, 2014

Mylan on Thursday announced that its subsidiary, Mylan Labs, was granted tentative approval from the Food and Drug Administration for two dosages of abacavir/lamivudine tablets for oral suspension. 

November 25, 2014

Mylan on Tuesday confirmed that it — along with several subsidiaries — has been sued by Baxter International, Baxter Healthcare Corp. and Baxter Healthcare S.A. in relation to the filing of an abbreviated new drug application for the generic version of Brevibloc. 

November 7, 2014

Mylan on Friday announced that it has signed an agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a severe allergic reaction. 

November 6, 2014

Mylan announced the launch of norethindrone acetate and ethinyl estradiol tablets USP, 1 mg/0.02 mg and ferrous fumarate, which is the generic equivalent to Loestrin 24 Fe from Warner Chilcott. 

October 31, 2014

Mylan on Friday announced the launch of nevirapine extended-release tablets in 400-mg strength, a generic version of Viramune XR from Boehringer Ingelheim. 

October 15, 2014

The U.S. Supreme Court on Wednesday heard arguments from Teva Pharmaceutical Industries in defense of the patent protecting its $4 billion multiple sclerosis drug Copaxone, according to a Reuters report. 

October 6, 2014

Mylan announced the launch of its lamivudine and zidovudine tablets USP, in 150-mg dosage strength.

September 15, 2014

Mylan announced that its subsidiary, Mylan Labs Limited, has signed an agreement with Gilead Science under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single-tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. 

September 10, 2014

Mylan announced that its subsidiary, Mylan Ireland Limited, has agreed to acquire the U.S. rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic version of Arixtra from Aspen Global. 

September 8, 2014

Mylan is now free to resume distribution of its generic Precedex product (dexmedetomidine hydrochloride injection) to customers, effective immediately. 

September 5, 2014

Mylan on Friday announced that it has launched a generic version of Hoffmann-La Roche's Boniva injection.

August 22, 2014

Mylan on Friday announced the launch of potassium chloride extended-release tablets USP in 600-mg and 750-mg dosage strengths.

August 19, 2014

The Food and Drug Administration has approved Mylan Institutional’s application for its dexmedetomidine hydrochloride injection, the company announced Tuesday. 

August 11, 2014

Mylan announced the launch of capecitabine tablets USP in 150-mg and 500-mg dosage strengths, a generic version of Xeloda tablets from Genentech.

July 23, 2014

Mylan on Wednesday announced that U.S. District Court for the district of New Jersey granted a temporary restraining order against Apotex Inc. and Apotex Corp. relating to Paroxetine CR.